UnknownNot Applicable

Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE

250 participantsStarted 2020-06-01

Plain-language summary

Pretransplant hepatoencephalopathy (HE) markedly impacts recipient outcomes after liver transplantation. Intraoperative CRRT showed benefits but feasibility was much concerned. This study aims to observe the effect on consciousness recovery when initiating CRRT early in the post-transplant period in recipients with ACLF and overt HE.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Pre transplant liver failure: Total bilirubin over 171μmol/L and prothrombin activity (PTA)\<40%;
. Overt hepatic encephalopathy(HE): Grade II or higher HE according West Haven classification;
. HE associated with acute liver failure (Type A) or cirrhosis complicated with portal hypertension and/or portal systemic shunts (Type C)

Exclusion criteria

. Patients with a previous history of kidney-related diseases and glomerular filtration rate \<30 millilitre per minute;
. Patients with acute renal failure need CRRT before transplantation;
. Patients newly developed acute renal failure need CRRT at the time of randomization;
. Retransplantation or multiple-organs transplantation;
. Any ischemic or hemorrhagic stroke co-morbidity;
. Hemodynamic instability requiring fluid resuscitation or very high dose of vasopressors;
. Extremely moribund patients with an expected life expectancy of less than 24 hours.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Consciousness recovery time

Timeframe: From the immediate to 30 days after liver transplantation

Adverse events

Timeframe: From the immediate to 7 days after liver transplantation (CRRT therapy period)

Trial details

NCT IDNCT04317222

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-31

Contact for this trial

Huimin Yi, doctor

18922102510 ylhmin@hotmail.com

View on ClinicalTrials.gov More Acute-On-Chronic Liver Failure trials